SCHEDULE 13G/A: Great Point Partners and Affiliates Disclose 6.25% Stake in Context Therapeutics

Great Point Partners, LLC, along with Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl, have jointly reported a beneficial ownership of 6.25% of Context Therapeutics Inc.'s common stock as of December 31, 2024.

Summary

• Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., and Ms. Lillian Nordahl have jointly filed an Amendment No. 2 to their Schedule 13G, disclosing their beneficial ownership in Context Therapeutics Inc.
• As of December 31, 2024, the reporting persons collectively beneficially own 4,683,711 shares of Context Therapeutics Inc. common stock.
• This ownership represents 6.25% of the total outstanding common stock of Context Therapeutics Inc., based on 74,998,310 shares reported by the issuer in its Form 10-Q filed on November 6, 2024.
• The shares are held by Biomedical Value Fund, L.P. (3,044,412 shares) and Biomedical Offshore Value Fund, Ltd. (1,639,299 shares), for which Great Point Partners, LLC acts as the investment manager.
• Dr. Jeffrey R. Jay, M.D., as Senior Managing Member, and Ms. Lillian Nordahl, as Managing Director of Great Point Partners, LLC, have shared voting and dispositive power over these shares.
• The reporting persons have certified that the securities were not acquired or held for the purpose of changing or influencing the control of Context Therapeutics Inc., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 5

Explanation: This document is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's operational or financial performance.

Risks

• The reporting persons explicitly certified that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer, mitigating potential risks associated with activist investor intentions.

Industry Context

This filing represents a standard disclosure of a significant passive investment by an investment firm in a publicly traded company, a common occurrence within the financial industry.

Corporate Governance

Stakeholder Impact

• Shareholders are informed of a significant passive stake held by an investment group, providing transparency regarding the ownership structure of the company.

Key Dates

Keywords

Context Therapeutics Inc., Common Stock, Schedule 13G, Beneficial Ownership, Great Point Partners, Jeffrey R. Jay, Lillian Nordahl, SEC filing, Investment Management, Shareholding